Astrazeneca ADR Stock
-
Your prediction
Astrazeneca ADR Stock
Pros and Cons of Astrazeneca ADR in the next few years
Pros
Cons
Performance of Astrazeneca ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Astrazeneca ADR | - | - | - | - | - | - | - |
| GSK plc ADR | -2.000% | -5.385% | 10.314% | 35.165% | 17.703% | 50.000% | 38.592% |
| Bayer AG ADR | -1.070% | -0.971% | -7.273% | 74.359% | 15.909% | -28.169% | -20.313% |
| UCB S.A. | 4.590% | -7.695% | -3.762% | 32.856% | 5.602% | 212.282% | 211.274% |
News
As Investors Flee U.S. Equities, This Global ETF Is Outperforming
Since the start of the year, investors have been vacating U.S. stocks and exchange-traded funds (ETFs) in a broad-based, risk-off strategy that has benefited safe-haven assets like gold and silver
After a Near 50% Drop, Tempus AI Could Be Ripe for a Rebound
Since going public in mid-2024, shares of healthcare and life science services company Tempus AI (NASDAQ: TEM) have gone on a wild rollercoaster ride. The firm’s initial public offering price
A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH
More than just a financial check-up, earnings for companies in the healthcare sector offer a key window for investors into a firm's pipeline and development progress. Even well-established, stable

